OncoMatch/Clinical Trials/NCT05208762
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Is NCT05208762 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including PF-08046054 and pembrolizumab for carcinoma, non-small-cell lung.
Treatment: PF-08046054 · pembrolizumab — This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have five parts. Parts A and B of the study will find out how much PF-08046054/SGN- PDL1V should be given to participants. Part C will use the dose found in Parts A and B to find out how safe PF-08046054/SGN-PDL1V is and if it works to treat solid tumor cancers. In Part D and E, participants will be given PF-08046054/SGN-PDL1V with pembrolizumab to find out how safe this combination is and if it works to treat solid tumor cancers.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Head and Neck Squamous Cell Carcinoma
Esophageal Carcinoma
Triple-Negative Breast Cancer
Breast Carcinoma
Gastric Cancer
Endometrial Cancer
Pancreatic Cancer
Hepatocellular Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) expression (historical PD-L1 testing required)
Participants must have PD-L1 expression based on historical testing
Required: PD-L1 (CD274) expression ≥1 or <1 by CPS or TPS (expression ≥1 or <1 by CPS or TPS)
Participants must have been previously tested for PD-L1 expression and should have PD-L1 expression ≥1 or <1 by CPS or TPS based on historical testing
Required: PD-L1 (CD274) expression ≥1% by TPS (expression ≥1% by TPS)
Participants with NSCLC; PD-L1 expression ≥ 1% by TPS
Required: PD-L1 (CD274) expression ≥1 by CPS (expression ≥1 by CPS)
Participants with HNSCC; PD--L1 expression ≥1 by CPS
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-L1 therapy
Exception: allowed if prior anti-PD-L1 agent was received ≥5 half-lives before study entry
Prior treatment with an anti-PD-L1 agent within less than 5 half-lives
Cannot have received: antibody-drug conjugate (MMAE-containing agent)
Previous receipt of an monomethylauristatin E (MMAE)-containing agent
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- University of Alabama at Birmingham, IDS Pharmacy · Birmingham, Alabama
- University of Alabama at Birmingham · Birmingham, Alabama
- University of Alabama at Birmingham · Birmingham, Alabama
- Chao Family Comprehensive Cancer Center and Ambulatory Care · Irvine, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify